ESR1 and breast carcinoma: Although IHC assessment of ERα and PR protein expression is recommended by the American Society of Clinical Oncology to guide breast cancer treatment; there is still a widely held perception that IHC is unreliable and inaccurate in a good proportion of cases [24], [45]–[47].